H.R. 10212: Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act

This bill would require the Department of Veterans Affairs (VA) to study peptide-based therapies and decide whether they should be used in VA medical settings for veterans.

What the bill requires

• The VA Secretary would first review existing federal regulations and guidance about peptides and create a clear definition of the term for this law.
• Within 180 days of enactment, the VA would have to send Congress a report describing:
  • the current regulations and guidance;
  • any new research developments since those rules were written;
  • the VA’s definition of “peptide”;
  • a definition of “peptide-based therapy”; and
  • the reasoning behind those definitions, including how they compare with other federal definitions.
• After that report is submitted, the VA would begin a study on the safety, effectiveness, and possible benefits of peptide-based therapies for veterans treated at VA facilities.

What the study would look at

The study would involve reviewing medical research, creating clinical protocols, and looking at possible uses for recovery, rehabilitation, chronic pain, mental health, physical wellness, and other service-connected conditions. It would also examine whether peptides are safe for clinical and rehabilitation use.

Possible pilot program

If the VA later concludes that peptide-based therapies should be made available to veterans, the bill would require the VA to run a pilot program. That program would allow veterans who choose to participate to receive peptide-based therapies, with the VA able to limit the program by geography, condition, or other factors.

The pilot program would last up to 5 years, and the VA would then have to report to Congress on:

• how well the therapies worked for different conditions;
• whether they should be expanded across VA medical facilities; and
• any problems or challenges encountered.

Overall effect

In practical terms, the bill does not immediately make peptide therapies available to veterans. Instead, it directs the VA to define the term, study the evidence, and potentially test these therapies in a limited pilot program before deciding whether to expand them more broadly.

Relevant Companies

None found